Isabelle Opitz

I was honored to attend the 43rd Annual Meeting of the Japanese Association for Chest Surgery (JACS) in Tsukuba. Proud to present on #oligometastaticdisease & #salvagesurgery during the ESTS–JACS joint session. Great to reconnect with Thoracic Surgery fellows from @Unispital_USZ – PARK SAMINA, Yoshito Yamada. Thanks to JACS leadership: Yukio Sato, Kenji Suzuki, Hisashi Saji, Shinichi Toyooka. #JACS2026 #Tsukuba #ThoracicSurgery #ChestSurgery #MedicalConference

The full program for #WCLC26 is now live! 🌏 Join the global thoracic oncology community in Seoul Sept. 12–15 for interactive sessions, debates, career-focused programming, and the latest science shaping #lungcancer care. ⏰ Receive early bird rates 🏨 Hotel rooms are limited Register now: bit.ly/4eIYgs0

🌟 Exciting Opportunity! 🌟 Assistant Professor– Surgery of Advanced Lung Diseases (100%) Department for Thoracic Surgery, University Hospital Zurich and University of Zurich Faculty of Medicine! We are seeking an ambitious surgeon-scientist to join our team: • Lead a research group and develop a precision medicine program for advanced lung diseases • Practice as a Senior Physician across the full spectrum of thoracic surgery, with potential future leadership of our transplantation program • Drive innovative clinical, translational, and experimental research Requirements: Board certification in thoracic or cardiac surgery, clinical leadership experience, strong research track record, and German proficiency B2 (or in progress). Start Date: by agreement Application Deadline: 31 July 2026 🔗 Apply now: [UZH: Assistant Professorship in Surgery for Advanced Functional Lung Disease] Take the next step in shaping the future of thoracic surgery and advanced lung disease care!

Exciting ! 🚀 Our phase III SalVage trial is now recruiting across multiple hospitals. This study explores whether adding local ablative treatment (surgery and/or radiotherapy) to standard therapy can improve survival and quality of life in patients with advanced NSCLC (stage IV). For patient referrals, please send us an email isabelle.schmitt-opitz@usz.ch and albana.rexhepajbaumann@usz.ch Home | ClinicalTrials.gov @Mat_Guc @MdCurioni @HeldUlrike @UszDidi @HillingerSven @OliviaLauk Gian-Marco Monsch @senbak68 @raph_werner Albana Rexhepaj #NSCLC #ClinicalTrial #Oncology #PatientCare #salVage

Congrats to the team on our latest article: “Pleural Infection in Adults: Integrating Medical and Surgical Management for Optimal Outcomes” A fantastic international collaboration between @Unispital_USZ @UniofOxford and @UniTrieste thank you to all contributors: Malvika Bhatnagar, Gian-Marco Monsch, Stefano Kette, @UszDidi @naj_rahman @eihab_bedawi Pleural infection remains a major global challenge. Outcomes depend heavily on timing, coordination, and interdisciplinary care. 🔑 Key takeaways: ✅ Delays in diagnosis & escalation worsen outcomes ✅ Reassess early — failure often evident within 48-72h ✅ tPA/DNase ≠ substitute for surgery in advanced disease ✅ Early surgical referral improves outcomes ✅ Close physician–surgeon collaboration is essential 📄Read more: Pleural Infection in Adults: Integrating Medical and Surgical Management for Optimal Outcomes - ScienceDirect

@maraantonoff @EGFRResisters @UTMDAnderson @nicolaszhoudo @lungoncdoc @AATSJournals @YoungLungCancer @ALKPositiveinc @OncogeneCancer Very interesting finding - pleurectomy to be performed though?

Findings from surgery after systemic tx in NSCLC with pleural mets: 📊 Imaging predicted pleural response, offering needed criteria in a space where clear benchmarks have been lacking 📈 Most pts (70.8%) had no residual pleural disease at surgery 🔗 jtcvsopen.org/article/S2666-…

A successful conclusion to the @ests_womenThor Academy Clinical Immersion in Zurich at the @Unispital_USZ ! Thanks to all involved, for making it unforgettable. 🚀 #ESTS #WGTS #ThoracicSurgery #WomenInSurgery #ClinicalImmersion

The ESTS WGTS Academy Clinical Immersion in Zurich is underway 🇨🇭

Honoured to be part of The Lancet Respiratory Medicine Podcast discussing the @EORTC - European Organisation for Research and Treatment of Cancer & @thoracic European Society of Thoracic Surgeons consensus on stage III NSCLC for clinical trials, with @a_dingemans and @finn_corinne. Hope you find our conversation useful to put the manuscript into perspective 🙏 🔗lnkd.in/eH99eGZQ 🎙️lnkd.in/eZMajTEs

Should we do molec testing on all NSCLCs? Answer: YES @JTOonline - 82328pts - 35.1% AGA+ (adeno=45.8% adenosq=40.9% sarcomatoid=29.1% NOS=27.6%, LCC=21.1% sq=6.5%) - age, sex, region assoc seen Congrats @Al3ssandroRusso @ChristianRolfo @oncoalert #LCSM jto.org/article/S1556-…

Happy to see so many surgeons contributing to #ELCC26 @IASLC discussing the role of surgery in early and late stage #Nsclc A truly MD meeting.👌✨ @OliviaLauk @raph_werner @pompili_cecilia Alessandro Brunelli Pierre Emmanuel Falcoz @ReneHPetersen @BrendonStilesMD Kenji Suzuki @giuliave1 @thoracic @myESMO @IASLC

It was a great pleasure- and looking forward to more discussions! @Yvonne_Diaz_ and Merel Hennick for putting this together ! #ELCC2026 @IASLC PATIENT ADVOCACY GROUP 🙏

@LindaMThoracic @JPatelMD @ALLIANCE_org @ROsarogiagbon @BrendonStilesMD @DoctorJSpicer @ElliotServaisMD @ChiFuJeffYang Congratulations @LindaMThoracic and team - impressive results esp N2 disease 👏

🫁 stage III N2+ (bx proven) operable Phase2 trial just published - CHIO3 ➡️multicenter trial 4 cycles neo-adj chemo + Durva ➡️N2 clearance 73% ➡️pCR 30%, mPR 50% ➡️93% R0 resections 🔪 ➡️93% lobectomy, 7% pneumonectomy ➡️0% mortality at 30 & 90d ✅surgery is feasible and should be considered in N2 🫁 cancer @tssmn @lcsmchat @STS_CTsurgery @GenThorSurgClub @LungCancerEu @IASLC @UVASurgery @UVACancerCenter @AmLungCSI @AstraZenecaUS @ests_womenThor @WomenInThoracic @thoracic ars.els-cdn.com/content/image/… sciencedirect.com/science/articl…

Are we ready for deintensification adjuvant IO in early-stage 🫁? In the future molecular and pathological parameters will guide our decisions? For pCR after induction CTIO we can discuss surveillance and in no-pCR probably continuing the same IO not the besst approach #ELCC26

Great debate D1 #ELCC26 betw ⁦@BrendonStilesMD⁩ and ⁦@_clarachan⁩ about rethinking resectability of stage III NSCLC: cutting the Dogma of IIIB with better 4Rs 🤞😉=> 2 B continued Tomorrow in the surgical session ⁦@raph_werner⁩: where are the limits of surgery

Life after transplant knows no limits 🏔️ January 2026: Lung & liver recipients from 🇨🇭🇦🇹🇺🇸🇭🇷🇩🇰 summited Aconcagua (6,960 m), raising organ donation awareness & proving courage & science can reach new heights. #OrganDonation #Aconcagua2026 #ThoracicSurgeryUSZ

🔜 #ELCC26 @myESMO 🇩🇰 🔥Defining the limits of surgery in lung cancer ☑️ #Segmentectomy #StageIII #Resectability 🎙️Chair: @IsaOpitz Dr. Kenji Suzuki @OncoAlert @Larvol #LCSM

Lung cancer is the biggest cancer killer of women in Europe yet it is rarely recognised as a women’s health issue. More women are being diagnosed across Europe, & in some countries deaths are still rising. Where you live, your income, and access to care can affect outcomes. When we talk about women’s health, #lungcancer must be part of the conversation. Women deserve better awareness, earlier diagnosis, & fair access to treatment. #InternationalWomensDay

Today on #InternationalWomensDay, we celebrate the women across the global thoracic oncology community who are making a difference every day. Clinicians, researchers, nurses, advocates, patients, and caregivers, your leadership and resilience continue to move the field forward. #IASLC #WomenInScience #LungCancer

🚨 Check our Top 10 #LungCancer abstracts for ELCC 2026! We've hand-picked the must-see sessions with times & presenters. 🗓️ Stay on track in Copenhagen and simply import these directly to your calendar by clicking this link: lungsummit.org/elcc2026.ics Which lung abstracts are your favorites at ELCC26 #LCSM @IASLC @myESMO